 |
 |
 |
 |
 |
 |
* Disclosures for Symposium S09 “What’s New in the Canadian Network for Mood and Anxiety Treatments (CANMAT) Depression Guidelines 2023 Update” presented at the Annual Meeting of the Canadian Psychiatric Association, October 20, 2023, Vancouver, BC, Canada.
- Dr. Raymond Lam: See disclosures below.
- Dr. Sidney Kennedy has received personal fees from Abbvie, Boehringer-Ingelheim, Janssen, Lundbeck, Merck, Neurotorium, Otsuka, Pfizer, Sunovion, and Servier; grants from Abbott, Brain Canada, Janssen, Otsuka, and Strategy for Patient-Oriented Research.
- Dr. Lena Quilty has no disclosures.
- Dr. Camelia Adams has no disclosures
- Dr. Andre Do has received honoraria for ad hoc speaking or advising/consulting, or received research funds, from: AbbVie, Canadian Institutes of Health Research and Otsuka.
Raymond W. Lam, MD, FRCPC, FCAHS
|
 |
Dr. Raymond W. Lam is Professor and BC Leadership Chair in Depression Research in the Faculty of Medicine, University of British Columbia (UBC), and the Associate Head for Graduate and Undergraduate Education in the UBC Department of Psychiatry. Dr. Lam is also Co-Director of the Mood Disorders Centre Research, Education, Awareness and Care Hub (MDCreach) at the Djavad Mowafaghian Centre for Brain Health in Vancouver. His research examines clinical and neurobiological factors in seasonal, treatment-resistant and workplace depression, clinical trials, clinical guidelines, digital health technologies, and global mental health. Dr. Lam is also a lead investigator for the Canadian Biomarker Integration Network in Depression (CAN-BIND) and Executive Chair of the Asia-Pacific Economic Cooperation (APEC) Digital Hub for Mental Health, hosted at UBC. His research is supported by many agencies and sponsors including the Canadian Institutes of Health Research.
Dr. Lam has published over 600 scientific articles and book chapters (including over 470 peer-reviewed papers), and edited or authored 11 books on depression. Google Scholar lists over 32,000 citations to his published work, with an h-index=94, and he is recognized by Clarivates Web of Science as a Highly-Cited Researcher (Top 1% of citations over the past decade in the Psychiatry/Psychology category, 2020-2022). He serves as Associate Editor for the Canadian Journal of Psychiatry and sits on the editorial boards of 4 international journals, including CNS Drugs. Dr. Lam is a champion for evidence-based medicine and is an editorial advisor for the international Cochrane Collaboration. He currently serves on the Board of Directors of Genome BC.
Dr. Lam has received many awards for his research and teaching, including the J.M. Cleghorn Award for Clinical Research (Canadian Psychiatric Association, 2015), a Distinguished Achievement Award for Overall Excellence (UBC Faculty of Medicine, 2022 & 2014), R.O. Jones Memorial Award (Canadian Psychiatric Association, 2007), Silver Anniversary Leadership Award (UBC Medical Alumni, 2006), and the inaugural Douglas Utting Prize and Medal for Depression Research (SMBD-JGH/McGill University, 2001). He is an elected Distinguished Fellow of both the Canadian Psychiatric Association and the American Psychiatric Association, a Foundation Fellow of the International Society for Affective Disorders, and the Past Executive Chair of the Canadian Network for Mood and Anxiety Treatments (CANMAT). In 2020, Dr. Lam was elected as a Fellow in the Canadian Academy of Health Sciences (CAHS), considered one of the highest honours for individuals in the Canadian health sciences community.
Recent Representative Publications
Rnic K, Lemoult J, Torres IJ, … Lam RW. Implicit self-depressed associations as a prognostic indicator of depressive recurrence following treatment: A Canadian Biomarker Integration Network in Depression (CAN-BIND) Study. Psychiatry Research, in revision, 2023.
Phaterpekar T, Nunez JJ, Morton E, … Lam RW. Machine learning prediction of quality of life improvement during antidepressant treatment of patients with major depressive disorder: A STAR*D and CAN-BIND-1 report. Journal of Clinical Psychiatry, in press, 2023
Murphy JK, Noble JM, Chakraborty PA, … Lam RW. Values and preferences related to workplace mental health programs and interventions: An international survey. PLoS One 18: e0283057, 2023.
Nunez JJ, Liu YS, Cao B, … Lam RW. Response trajectories during escitalopram treatment of patients with major depressive disorder. Psychiatry Research 327:115361, 2023.
Cheung BSW, Murphy JK, Michalak EE, … Chen J, Lam RW. Barriers and facilitators to technology-enhanced measurement-based care for depression among Canadian clinicians and patients: Results of an online survey. Journal of Affective Disorders 320:1-6, 2023.
Tham JCW, Do A, … Lam RW. Repeated subcutaneous racemic ketamine in treatment-resistant depression: Case series. International Clinical Psychopharmacology 37:206-214, 2022.
Do A, Li VW, Huang S, Michalak EE, Murphy JK, Yatham LN, Lam RW. Blue-light therapy for seasonal and non-seasonal depression: A systematic review and meta-analysis of randomized controlled trials. Canadian Journal of Psychiatry 67:745-754, 2022.
Huang L, Li VW, Yang T, Liu J, Murphy JK, Michalak EE, Wang Z, Ng CH, Yatham LN, Chen J, Lam RW. Mobile health applications for depression in China: A systematic review. Cureus 14:e27299, 2022.
Murphy JK, Maulik P, Dobson K, Govia I, Lam RW, … Pearson M. Advancing implementation science measurement for global mental health research.Canadian Journal of Psychiatry 67:428-431, 2022.
Li VW, Morton E, Michalak EE, … Lam RW. Functional outcomes with bright light in monotherapy and combined with fluoxetine in patients with major depressive disorder: Results from the LIFE-D trial. Journal of Affective Disorders 297:396-400, 2022.
Rnic K, Jung YE, Torres IJ, … Lam RW. Association between discrepancy in objective and subjective cognitive abilities and treatment response in patients with major depressive disorder: A CAN-BIND-1 study report. Journal of Affective Disorders 295:1095-1101, 2021.
Murphy JK, Michalak EE, Liu J, … Lam RW. Barriers and facilitators to implementing measurement-based care for depression in Shanghai, China: A situational analysis. BMC Psychiatry 21:430, 2021.
Zhu M, Hong RH, Yang T, … Lam RW. The efficacy of measurement-based care for depressive disorders: A systematic review and meta-analysis of randomized controlled trials. Journal of Clinical Psychiatry 82:21r14034, 2021.
Nunez JJ, Nguyen T, Zhou Y, … Lam RW. Replication of machine learning methods to predict treatment outcome with antidepressant medications in patients with major depressive disorder from STAR*D and CAN-BIND-1. PLoS One 16: e0253023, 2021.
Murphy JK, Khan A, Michalak EE, … Lam RW. Needs, gaps and opportunities for standard and e-mental health care among at-risk populations in the Asia Pacific in the context of COVID-19: A rapid scoping review. International Journal for Equity in Health 20:161, 2021.
Morton E, Bhat V, Giacobbe P, … Lam RW. Predictors of quality of life improvement with escitalopram and adjunctive aripiprazole in patients with major depressive disorder: A CAN-BIND study report. CNS Drugs 35:439-450, 2021.
McGirr A, Vila-Rodriguez F, Cole J… Lam RW, Chakrabarty T, Yatham LN. Efficacy of intermittent theta burst transcranial magnetic stimulation for bipolar depression: A randomized clinical trial. JAMA Network Open 4: e210963, 2021.
Morton E, Michalak EE, Levitt AJ, … Lam RW. Quality of life impacts of bright light treatment, fluoxetine, and the combination in patients with nonseasonal major depressive disorder: A randomized clinical trial. Canadian Journal of Psychiatry 66:289-297, 2021.
Chakrabarty T, McInerney S, Torres IJ, … Lam RW. Cognitive outcomes with sequential escitalopram monotherapy and adjunctive aripiprazole treatment in major depressive disorder: A Canadian Biomarker Integration Network in Depression (CAN-BIND) report. CNS Drugs 35:291-304, 2021.
Swainson J, McGirr A, Blier P, … Lam RW. The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force recommendations for the use of racemic ketamine in patients with major depressive disorder. Canadian Journal of Psychiatry 66:113-125, 2021.
Hong RH, Murphy JK, Michalak EE, Chakrabarty T, Wang Z, Parikh SV, Culpepper L, Yatham LN, Lam RW (co-senior author), Chen J (co-senior author). Implementing measurement-based care for depression: Practical solutions for psychiatrists and primary care physicians. Neuropsychiatric Disease and Treatment 17:79-90, 2021.
McInerney SJ, Chakrabarty T, Maciukiewicz M, … Lam RW. Cognition and its association with functional outcomes during antidepressant treatment in patients with major depressive disorder: A CAN-BIND-1 report. Canadian Journal of Psychiatry 66:798-806, 2021.
Yang T, Chen J, Lam RW, Fang Y, Xu Y. Mental health service challenges during the COVID-19 pandemic: Experience and best practices from China. Canadian Journal of Psychiatry 66:621-623, 2021.
Gratzer D, Torous J, Vigo D, Lam RW, et al. Our digital moment: Innovations and opportunities in digital mental health care. Canadian Journal of Psychiatry 66:5-8, 2021.
Chakrabarty T, Harkness KL, … Lam RW. Childhood maltreatment and cognitive functioning in patients with major depressive disorder: A CAN-BIND-1 report. Psychological Medicine 50:2536-2537, 2020.
Dowrick C, Kassai R, Lam CLK, Lam RW, et al. APEC Digital Hub for Mental Health and WONCA Collaboration: Integrating mental health into primary care. Journal of Multidisciplinary Healthcare 13:1693-1704, 2020.
Lam RW, Teng MY, Jung YE, Evans VC, Gottlieb JF, Michalak EE, Murphy JK, Chakrabarty T, Yatham LN, Sit DK. Light therapy for patients with bipolar depression: Systematic review and meta-analysis of randomized clinical trials. Canadian Journal of Psychiatry 65:290-300, 2020.
Kennedy SH, Lam RW, Rotzinger S, et al. Symptomatic and functional outcomes and early prediction of response to escitalopram monotherapy and sequential aripiprazole therapy in patients with major depressive disorder: A CAN-BIND-1 report. Journal of Clinical Psychiatry 80: pii: 18m12202, 2019.
Murphy JK, Michalak EE, Colquhoun H, Ng CH, Parikh SV, Culpepper L, Dewa CS, Greenshaw AJ, He Y, Kennedy SH, Li XM, Liu TL, Soares C, Upshall P, Wang ZW, Xu Y, Chen J, Lam RW. Methodological approaches to situational analysis in global mental health: a scoping review. Global Mental Health 6:e11, 2019.
Alonso-Prieto E, Rubino C, Lucey M, Evans VC, Tam EM, Woo C, Iverson GI, Chakrabarty T, Yatham LN, Lam RW. Self-reported cognitive complaints in patients with major depressive disorder treated with desvenlafaxine: Relationships to work functioning. Psychiatry Research 272:144-148, 2019.
Ng C, Goodenow MM, Greenshaw AJ, Upshall P, Lam RW. Inclusion of mental health in global economic development. BJPsych International 15:74-76, 2018.
Lam RW, Lamy F-X, Danchenko N,et al. Psychometric validation of the Perceived Deficits Questionnaire-Depression (PDQ-D) instrument in US and UK respondents with major depressive disorder. Neuropsychiatric Disease and Treatment 14:2861-2877, 2018.
Levitan RD, Levitt AJ, Michalak EE, Cheung A, Morehouse R, Ramasubbu R, Yatham LN, Tam EM, Lam RW. Appetitive symptoms differentially predict treatment response to medication, light and placebo in non-seasonal major depression. Journal of Clinical Psychiatry 79:17m11856, 2018.
Sarfati D, Evans VC, Iverson GI, Woo C, Yatham LN, Lam RW. The impact of fatigue and energy on work impairment in patients with major depressive disorder treated with desvenlafaxine. International Clinical Psychopharmacology 32:343-349, 2017.
Lam RW, McIntosh D, Wang JL, et al. CANMAT 2016 clinical guidelines for the management of adults with major depressive disorder. Section 1. Disease burden and principles of care. Canadian Journal of Psychiatry 61: 510-523, 2016.
Kennedy SH (co-1st author), Lam RW (co-1st author), McIntyre RS,et al. CANMAT 2016 clinical guidelines for the management of adults with major depressive disorder. Section 3. Pharmacological treatments. Canadian Journal of Psychiatry, 61:540-560, 2016.
Evans VC, Alamian G, McLeod J, Woo C, Yatham LN, Lam RW. Effects of newer antidepressants on occupational impairment in major depressive disorder: A systematic review and meta-analysis of randomized controlled trials. CNS Drugs 30:405-417, 2016.
Lam RW, Levitt AJ, Levitan RD, Michalak EE, Cheung A, Morehouse R, Ramasubbu R, Yatham LN, Tam EM. Efficacy of bright light treatment, fluoxetine, and the combination in patients with nonseasonal major depressive disorder: a randomized clinical trial. JAMA Psychiatry 73:56-63, 2016.
Lam RW, Milev R, Rotzinger S, et al. Discovering biomarkers for antidepressant response: Protocol from the Canadian Biomarker Integration Network in Depression (CAN-BIND) and clinical characteristics of the first patient cohort. BMC Psychiatry 16:105, 2016.
Lam RW, Iverson GI, Evans VC, Yatham LN, Stewart K, Tam EM, Axler A, Woo C. The effects of desvenlafaxine on neurocognitive and work functioning in employed outpatients with major depressive disorder. Journal of Affective Disorders 203:55-61, 2016.
McGirr A, Berlim MT, Bond DJ, Fleck MP, Yatham LN, Lam RW. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychological Medicine 45:693-704, 2015.
Song C, Luchtman D, Kang Z, Tam EM, Yatham LN, Su KP, Lam RW. Enhanced inflammatory and T-helper-1 type responses but suppressed lymphocyte proliferation in patients with seasonal affective disorder and treated by light therapy. Journal of Affective Disorders 185:90-96, 2015.
Evans VC, Iverson GL, Yatham LN, Lam RW. The relationship between neurocognitive and psychosocial functioning in major depressive disorder: A systematic review. Journal of Clinical Psychiatry 75:1359-1370, 2014.
Lam RW, Parikh SV, Ramasubbu R, Michalak EE, Tam EM, Axler A, Yatham LN, Kennedy SH, Manjunath CV. Effects of combined pharmacotherapy and psychotherapy for improving work functioning in major depressive disorder. British Journal of Psychiatry 203:358-365, 2013.
Potential Conflict of Interest Disclosures (2021-2023)
The following are the sources of all income from commercial, not-for-profit, and government organizations (outside of academic salary from the University of British Columbia and clinical income from the BC Ministry of Health).
Ad Hoc Speaker Honoraria: Carnot, Lundbeck, Otsuka, Pfizer/Viatris, Shanghai Mental Health Center.
Ad Hoc Consulting/Advisory Boards: Abbvie, Asia-Pacific Economic Cooperation, Bausch, Canadian Network for Mood and Anxiety Treatments, CB Solutions, GenomeBC, Medscape, Neurotorium, Sunnybrook Health Sciences Center, Otsuka.
Research Funds (administered through UBC): BC Leading Edge Endowment Fund, Boehringer-Ingelheim, Brain Canada, Canadian Institutes of Health Research, Canadian Network for Mood and Anxiety Treatments, Grand Challenges Canada, Healthy Minds Canada, Janssen, Michael Smith Foundation for Health Research, MITACS, Ontario Brain Institute, Unity Health, Vancouver Coastal Health Research Institute, VGH-UBCH Foundation.
Patents/Copyrights: Lam Employment Absence and Productivity Scale (LEAPS).
Book Royalties: Cambridge University Press, Informa Press, Oxford University Press.
Stock/Stock Options: None.
Gifts/Travel (unrelated to speaker expenses): None.
Speaker Boards: None.